$APVO
Aptevo Therapeutics Inc.

2017 Q1 Form 10-Q Financial Statement

#000156459017010737 Filed on May 12, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2016 Q1
Revenue $2.142M $8.067M
YoY Change -73.45% -30.83%
Cost Of Revenue $488.0K $3.528M
YoY Change -86.17% -5.42%
Gross Profit $1.654M $4.539M
YoY Change -63.56% -42.76%
Gross Profit Margin 77.22% 56.27%
Selling, General & Admin $10.55M $9.419M
YoY Change 11.98% -5.15%
% of Gross Profit 637.67% 207.51%
Research & Development $5.913M $8.101M
YoY Change -27.01% -10.98%
% of Gross Profit 357.5% 178.48%
Depreciation & Amortization $841.0K $836.0K
YoY Change 0.6% 41.69%
% of Gross Profit 50.85% 18.42%
Operating Expenses $16.46M $17.52M
YoY Change -6.05% -7.98%
Operating Profit -$9.539M -$12.98M
YoY Change -26.52% 16.92%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$406.0K $80.00K
YoY Change -607.5% -126.67%
Pretax Income -$9.945M -$12.90M
YoY Change -22.91% 13.2%
Income Tax -$820.0K -$12.00K
% Of Pretax Income
Net Earnings -$9.945M -$12.89M
YoY Change -22.84% 16.94%
Net Earnings / Revenue -464.29% -159.77%
Basic Earnings Per Share -$0.48
Diluted Earnings Per Share -$6.723M -$8.951M
COMMON SHARES
Basic Shares Outstanding 20.76M
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q1 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $60.90M $3.100M
YoY Change 1864.52%
Cash & Equivalents $14.41M $3.072M
Short-Term Investments $46.90M
Other Short-Term Assets $6.500M $5.400M
YoY Change 20.37%
Inventory $8.100M $22.10M
Prepaid Expenses
Receivables $1.900M $3.500M
Other Receivables $0.00 $1.300M
Total Short-Term Assets $77.40M $35.40M
YoY Change 118.64%
LONG-TERM ASSETS
Property, Plant & Equipment $6.400M $4.600M
YoY Change 39.13%
Goodwill $29.21M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $20.40M $92.52M
YoY Change -77.95%
TOTAL ASSETS
Total Short-Term Assets $77.40M $35.40M
Total Long-Term Assets $20.40M $92.52M
Total Assets $97.80M $127.9M
YoY Change -23.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.800M $12.20M
YoY Change -27.87%
Accrued Expenses $2.500M $2.200M
YoY Change 13.64%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $14.50M $18.70M
YoY Change -22.46%
LONG-TERM LIABILITIES
Long-Term Debt $18.40M $0.00
YoY Change
Other Long-Term Liabilities $3.400M $3.500M
YoY Change -2.86%
Total Long-Term Liabilities $21.80M $3.500M
YoY Change 522.86%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.50M $18.70M
Total Long-Term Liabilities $21.80M $3.500M
Total Liabilities $36.30M $38.05M
YoY Change -4.61%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $61.50M $89.86M
YoY Change
Total Liabilities & Shareholders Equity $97.80M $112.6M
YoY Change -13.14%

Cashflow Statement

Concept 2017 Q1 2016 Q1
OPERATING ACTIVITIES
Net Income -$9.945M -$12.89M
YoY Change -22.84% 16.94%
Depreciation, Depletion And Amortization $841.0K $836.0K
YoY Change 0.6% 41.69%
Cash From Operating Activities -$12.03M -$14.11M
YoY Change -14.74% -11.37%
INVESTING ACTIVITIES
Capital Expenditures $794.0K $1.071M
YoY Change -25.86% -865.0%
Acquisitions
YoY Change
Other Investing Activities -$2.040M
YoY Change
Cash From Investing Activities -$2.830M -$1.070M
YoY Change 164.49% 664.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 19.20M 13.62M
YoY Change 40.97% -5.29%
NET CHANGE
Cash From Operating Activities -12.03M -14.11M
Cash From Investing Activities -2.830M -1.070M
Cash From Financing Activities 19.20M 13.62M
Net Change In Cash 4.338M -1.560M
YoY Change -378.08% -7.14%
FREE CASH FLOW
Cash From Operating Activities -$12.03M -$14.11M
Capital Expenditures $794.0K $1.071M
Free Cash Flow -$12.82M -$15.18M
YoY Change -15.53% -3.8%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q3 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
35000000
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1678000
CY2017Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
990000
CY2017Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9945000
CY2016Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12901000
CY2016Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-12000
CY2017Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1424000
CY2017Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2358000
CY2016Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2998000
CY2017Q1 apvo Collaborations Revenue
CollaborationsRevenue
28000
CY2016Q1 apvo Collaborations Revenue
CollaborationsRevenue
119000
CY2017Q1 us-gaap Sales Revenue Net
SalesRevenueNet
7409000
CY2016Q1 us-gaap Sales Revenue Net
SalesRevenueNet
8067000
CY2017Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
488000
CY2016Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
3528000
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5913000
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8101000
CY2017Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
10547000
CY2016Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9419000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-9539000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-12981000
CY2017Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-406000
CY2016Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
80000
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-406000
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
80000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-9945000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-12889000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.48
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.64
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20757111
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20229849
CY2017Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-8000
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9953000
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12889000
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
334000
CY2016Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
836000
CY2016Q1 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-12000
CY2016Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-31000
CY2016Q1 apvo Increase Decrease In Sales Rebates And Discounts
IncreaseDecreaseInSalesRebatesAndDiscounts
278000
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1071000
CY2016Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1749000
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
550000
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3093000
CY2017Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-4182000
CY2016Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
1347000
CY2017Q1 apvo Increase Decrease In Sales Rebates And Discounts
IncreaseDecreaseInSalesRebatesAndDiscounts
925000
CY2017Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-27000
CY2016Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1575000
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-12027000
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-14112000
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
794000
CY2017Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
10138000
CY2017Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
8102000
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-2830000
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1071000
CY2017Q1 apvo Payments For Taxes Related To Net Share Settlement Of Equity Awards
PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards
805000
CY2017Q1 apvo Proceeds From Former Parent
ProceedsFromFormerParent
20000000
CY2016Q1 us-gaap Proceeds From Contributions From Parent
ProceedsFromContributionsFromParent
13800000
CY2016Q1 apvo Contingent Consideration Payments
ContingentConsiderationPayments
181000
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
19195000
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
13619000
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
4338000
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1564000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4636000
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3072000
CY2017Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</p></div>
CY2017Q1 apvo Number Of Revenue Generating Products
NumberOfRevenueGeneratingProducts
4
CY2017Q1 apvo Entity Incorporation Month And Year Of Incorporation
EntityIncorporationMonthAndYearOfIncorporation
2016-02
CY2017Q1 apvo Date Of Spinoff
DateOfSpinoff
2016-08-01
CY2017Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
54031000
CY2016Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
50064000
CY2017Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2017Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2017Q1 us-gaap Inventory Raw Materials And Supplies Net Of Reserves
InventoryRawMaterialsAndSuppliesNetOfReserves
224000
CY2016Q4 us-gaap Inventory Raw Materials And Supplies Net Of Reserves
InventoryRawMaterialsAndSuppliesNetOfReserves
260000
CY2017Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1571000
CY2016Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1165000
CY2017Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
6268000
CY2016Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
5214000
CY2017Q1 us-gaap Line Of Credit Facility Frequency Of Payment And Payment Terms
LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms
The loan repayment will include interest (no principal) through August 2018. Commencing in August 2018, the payments will include principal and interest and will be repaid in full on February 1, 2021 (54 months).
CY2016Q3 us-gaap Line Of Credit Facility Expiration Period
LineOfCreditFacilityExpirationPeriod
P54M
CY2016Q3 us-gaap Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
2021-02-01
CY2017Q1 us-gaap Debt Instrument Description Of Variable Rate Basis
DebtInstrumentDescriptionOfVariableRateBasis
LIBOR
CY2016Q3 us-gaap Debt Instrument Basis Spread On Variable Rate1
DebtInstrumentBasisSpreadOnVariableRate1
0.0760
CY2017Q1 us-gaap Due From Other Related Parties
DueFromOtherRelatedParties
20000000
CY2017Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
1900000
CY2017Q1 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
1600000
CY2016Q3 apvo Credit Agreement Exit Fee Percentage
CreditAgreementExitFeePercentage
0.0575
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1678000
CY2016Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2693000

Files In Submission

Name View Source Status
0001564590-17-010737-index-headers.html Edgar Link pending
0001564590-17-010737-index.html Edgar Link pending
0001564590-17-010737.txt Edgar Link pending
0001564590-17-010737-xbrl.zip Edgar Link pending
apvo-10q_20170331.htm Edgar Link pending
apvo-20170331.xml Edgar Link completed
apvo-20170331.xsd Edgar Link pending
apvo-20170331_cal.xml Edgar Link unprocessable
apvo-20170331_def.xml Edgar Link unprocessable
apvo-20170331_lab.xml Edgar Link unprocessable
apvo-20170331_pre.xml Edgar Link unprocessable
apvo-ex101_309.htm Edgar Link pending
apvo-ex311_307.htm Edgar Link pending
apvo-ex312_306.htm Edgar Link pending
apvo-ex321_304.htm Edgar Link pending
apvo-ex322_305.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending